SEARCH:   Advanced

Blood, 15 December 2004, Vol. 104, No. 13, pp. 3858-3864. Prepublished online as a Blood First Edition Paper on August 24, 2004; DOI 10.1182/blood-2004-06-2223. This Article Full Text (PDF) Erratum (v105,p2257) All Versions of this Article: 2004-06-2223v1 104/13/3858    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Roberts, H. R Articles by White, G. C Search for Related Content PubMed PubMed Citation Articles by Roberts, H. R Articles by White, G. C Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 14, 2004 Accepted August 10, 2004 The use of recombinant factor VIIa in the treatment of bleeding disorders Harold R Roberts*, Dougald M Monroe, and Gilbert C White Division of Hematology/Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA * Corresponding author; email: hrr{at}med.unc.edu. Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to Factors VIII and IX respectively. After its introduction, it has also been used "off-label" to enhance hemostasis in non-hemophilic patients who experience bleeding episodes not responsive to conventional therapy. Evidence so far indicates that the use of factor VIIa in hemophilic patients with inhibitors is both safe and effective. Anecdotal reports also suggest that the product is safe and effective in controlling bleeding in non-hemophilic patients, However, its use in these conditions has not been approved by the FDA and conclusive evidence of its effectiveness from controlled clinical trials is not yet available. Several questions pertaining to the use of factor VIIa require further investigation including: the mechanism of action; the optimal dose; definitive indications; ultimate safety; and laboratory tests for monitoring therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Huth-Kuhne, F. Baudo, P. Collins, J. Ingerslev, C. M. Kessler, H. Levesque, M. E. M. Castellano, M. Shima, and J. St-Louis International recommendations on the diagnosis and treatment of patients with acquired hemophilia A Haematologica, April 1, 2009; 94(4): 566 - 575. [Abstract] [Full Text] [PDF] C. L. Kempton and G. C. White II How we treat a hemophilia A patient with a factor VIII inhibitor Blood, January 1, 2009; 113(1): 11 - 17. [Abstract] [Full Text] [PDF] C. Weeterings, P. G. de Groot, J. Adelmeijer, and T. Lisman The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface Blood, October 15, 2008; 112(8): 3227 - 3233. [Abstract] [Full Text] [PDF] M. Franchini and G. Lippi Acquired factor VIII inhibitors Blood, July 15, 2008; 112(2): 250 - 255. [Abstract] [Full Text] [PDF] K. D. Rand, M. D. Andersen, O. H. Olsen, T. J. D. Jorgensen, H. Ostergaard, O. N. Jensen, H. R. Stennicke, and E. Persson The Origins of Enhanced Activity in Factor VIIa Analogs and the Interplay between Key Allosteric Sites Revealed by Hydrogen Exchange Mass Spectrometry J. Biol. Chem., May 9, 2008; 283(19): 13378 - 13387. [Abstract] [Full Text] [PDF] L. H. Edmunds Jr and R. W. Colman Bleeding That Won't Stop Ann. Thorac. Surg., April 1, 2008; 85(4): 1153 - 1154. [Full Text] [PDF] J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, October 16, 2007; 116(16): e391 - e413. [Abstract] [Full Text] [PDF] J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, June 1, 2007; 38(6): 2001 - 2023. [Abstract] [Full Text] [PDF] P. M. Mannucci and M. Levi Prevention and Treatment of Major Blood Loss N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311. [Full Text] [PDF] O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714. [Abstract] [Full Text] [PDF] P. K. Gopalan, J. C. Clohisy, A. F. Cashen, and C. S. Eby Use of Recombinant Factor VIIa for Hip Surgery in a Patient with Factor-VII Deficiency. A Case Report J. Bone Joint Surg. Am., February 1, 2007; 89(2): 389 - 391. [Full Text] [PDF] L. H. Edmunds Jr and R. W. Colman Thrombin During Cardiopulmonary Bypass Ann. Thorac. Surg., December 1, 2006; 82(6): 2315 - 2322. [Abstract] [Full Text] [PDF] K. M. Bowles, C. J. Callaghan, A. L. Taylor, R. J. Harris, G. J. Pettigrew, T. P. Baglin, and G. R. Park Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage Br. J. Anaesth., October 1, 2006; 97(4): 476 - 481. [Abstract] [Full Text] [PDF] A. J Yee and D. J Kuter Successful Recovery After an Overdose of Argatroban Ann. Pharmacother., February 1, 2006; 40(2): 336 - 339. [Abstract] [Full Text] [PDF] W. K. Hoots Challenges in the Therapeutic Use of a "So-Called" Universal Hemostatic Agent: Recombinant Factor VIIa Hematology, January 1, 2006; 2006(1): 426 - 431. [Abstract] [Full Text] [PDF] V. B. Louvain-Quintard, E. P. Bianchini, C. Calmel-Tareau, M. Tagzirt, and B. F. Le Bonniec Thrombin-activable Factor X Re-establishes an Intrinsic Amplification in Tenase-deficient Plasmas J. Biol. Chem., December 16, 2005; 280(50): 41352 - 41359. [Abstract] [Full Text] [PDF] Y.-M. Sun, D.-Y. Jin, R. M. Camire, and D. W. Stafford Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X Blood, December 1, 2005; 106(12): 3811 - 3815. [Abstract] [Full Text] [PDF] M. S. Lam and R. P Sims-McCallum Recombinant Factor VIIa in the Treatment of Non-Hemophiliac Bleeding Ann. Pharmacother., May 1, 2005; 39(5): 885 - 891. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020